Safety and feasibility of third-party multipotent adult progenitor cells for immunomodulation therapy after liver transplantation--a phase I study (MISOT-I)

BACKGROUND: Liver transplantation is the definitive treatment for many end-stage liver diseases. However, the life-long immunosuppression needed to prevent graft rejection causes clinically significant side effects. Cellular immunomodulatory therapies may allow the dose of immunosuppressive drugs to...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Popp, Felix C, Fillenberg, Barbara, Eggenhofer, Elke, Renner, Philipp, Dillmann, Johannes, Benseler, Volker, Schnitzbauer, Andreas A, Hutchinson, James, Deans, Robert, Ladenheim, Deborah, Graveen, Cheryl A, Zeman, Florian, Koller, Michael, Hoogduijn, Martin J, Geissler, Edward K, Schlitt, Hans J, Dahlke, Marc H
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2011
Assuntos:
Protocol
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3166276/
https://ncbi.nlm.nih.gov/pubmed/21798013
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-9-124
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados